TrialInvestigational new drugs2021

Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study).

Toshinari Yamashita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.